Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 12/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 12/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13605108 | 0.87 | TAS1R3 (0.49) | TAS1R3TAS1R1L3MBTL1GAARAB9A | |
| SCHEMBL5901366 | 0.83 | NOS3 (0.49) | TAS1R3TAS1R1L3MBTL1GAARAB9A | |
| SCHEMBL29241144 | 0.82 | TAS1R3 (0.50) | TAS1R3TAS1R1L3MBTL1GAARAB9A | |
| SCHEMBL29241142 | 0.82 | TAS1R3 (0.50) | TAS1R3TAS1R1L3MBTL1GAARAB9A | |
| SCHEMBL13612957 | 0.81 | L3MBTL1 (0.69) | TAS1R3TAS1R1L3MBTL1GAARAB9A | |
| SCHEMBL13885653 | 0.81 | LNPEP (0.56) | TAS1R3TAS1R1L3MBTL1GAARAB9A | |
| SCHEMBL12983609 | 0.81 | TAS1R3 (0.52) | TAS1R3TAS1R1L3MBTL1GAARAB9A | |
| SCHEMBL12983607 | 0.81 | TAS1R3 (0.52) | TAS1R3TAS1R1L3MBTL1GAARAB9A | |
| SCHEMBL21663897 | 0.80 | TAS1R3 (0.50) | TAS1R3TAS1R1L3MBTL1GAARAB9A | |
| SCHEMBL5995873 | 0.80 | ALDH1A1 (0.51) | TAS1R3TAS1R1L3MBTL1GAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139597-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY (BM) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139597-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | KIT, PRKCH, PRKCE | TAS1R3 2202/4885TAS1R1 2142/4885L3MBTL1 4630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.